Indacaterol in chronic obstructive pulmonary disease: An update for clinicians

Simple item page
dc.contributor.authorYorgancioglu A.
dc.date.accessioned2024-07-22T08:19:44Z
dc.date.available2024-07-22T08:19:44Z
dc.date.issued2012
dc.description.abstractBronchodilation is the cornerstone of chronic obstructive pulmonary disease (COPD) management and is based on regular treatment with one or more long-acting β2 agonists (LABAs). A novel bronchodilator, indacaterol, satisfies the requirements of an efficacious LABA: it has a relatively longer duration of action compared with existing LABAs and a fast onset of action. This review is a presentation of data on indacaterol with respect to its molecular characteristics as well as comparisons with other long-acting bronchodilators. Data from 12 relevant trials show that once-daily indacaterol provides significant, consistent and clinically important improvements in lung function (forced expiratory volume in 1 second), significant improvements in breathlessness and health status at least as good as or better than tiotropium, salmeterol and formoterol, and reduction in requirement for relief medication compared with tiotropium, salmeterol and formoterol. © 2012, SAGE Publications. All rights reserved.
dc.identifier.DOI-ID10.1177/2040622311426204
dc.identifier.issn20406223
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17814
dc.language.isoEnglish
dc.rightsAll Open Access; Bronze Open Access; Green Open Access
dc.subjectcorticosteroid
dc.subjectfluticasone
dc.subjectformoterol
dc.subjectindacaterol
dc.subjectplacebo
dc.subjectsalbutamol
dc.subjectsalmeterol
dc.subjecttiotropium bromide
dc.subjectbinding affinity
dc.subjectbronchodilatation
dc.subjectbronchospasm
dc.subjectcardiovascular disease
dc.subjectcerebrovascular disease
dc.subjectchronic obstructive lung disease
dc.subjectclinical feature
dc.subjectcoughing
dc.subjectdisease exacerbation
dc.subjectdose response
dc.subjectdrug absorption
dc.subjectdrug dose comparison
dc.subjectdrug dose increase
dc.subjectdrug effect
dc.subjectdrug efficacy
dc.subjectdrug half life
dc.subjectdrug mechanism
dc.subjectdrug potency
dc.subjectdrug safety
dc.subjectdrug structure
dc.subjectdrug tolerability
dc.subjectdrug withdrawal
dc.subjectdyspnea
dc.subjectforced expiratory volume
dc.subjectglucose blood level
dc.subjectheart disease
dc.subjectheart infarction
dc.subjecthuman
dc.subjectinfection
dc.subjectinfestation
dc.subjectinspiratory capacity
dc.subjectlipophilicity
dc.subjectmediastinum disease
dc.subjectnonhuman
dc.subjectoutcome assessment
dc.subjectpatient compliance
dc.subjectpotassium blood level
dc.subjectpriority journal
dc.subjectQT prolongation
dc.subjectquality of life
dc.subjectrespiratory tract disease
dc.subjectreview
dc.subjectrhinopharyngitis
dc.subjectside effect
dc.subjectsingle drug dose
dc.subjectthorax disease
dc.subjecttime to maximum plasma concentration
dc.subjecttreatment duration
dc.titleIndacaterol in chronic obstructive pulmonary disease: An update for clinicians
dc.typeReview

Files

Collections

Scopus Koleksiyonu